Atlas Trials

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Clinical trial NCT04366713 · COMPLETED

Trial details

NCT number
NCT04366713
Sponsor
Puma Biotechnology, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Amplified Breast Cancer
Start date
2020-06-30
Primary completion
2021-12-28
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.